| Symbol | APGE |
|---|---|
| Name | APOGEE THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | 221 CRESCENT STREET,BUILDING 17,SUITE 102B, WALTHAM, Massachusetts, 02453, United States |
| Telephone | +1 650 394-5230 |
| Fax | — |
| — | |
| Website | https://www.apogeetherapeutics.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | — |
| Description | Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts. Additional info from NASDAQ: |
New Form ARS - Apogee Therapeutics, Inc. <b>Filed:</b> 2026-04-24 <b>AccNo:</b> 0001193125-26-177361 <b>Size:</b> 3 MB
Read moreDirector HENDERSON MICHAEL THOMAS 🟡 adjusted position in 0 shares (1 derivative) of Apogee Therapeutics, Inc. (APGE) at $22.86 Transaction Date: Apr 16, 2026 | Filing ID: 045482
Read moreHenderson Jane 🔴 sold 2.0K shares of Apogee Therapeutics, Inc. (APGE) at $90.00 Transaction Date: Apr 16, 2026 | Filing ID: 045062
Read moreDirector HENDERSON MICHAEL THOMAS 🔴 sold 20.0K shares of Apogee Therapeutics, Inc. (APGE) at $85.00 ($1.7M) Transaction Date: Apr 08, 2026 | Filing ID: 042155
Read moreNew Form SCHEDULE 13G/A - Apogee Therapeutics, Inc. <b>Filed:</b> 2026-04-08 <b>AccNo:</b> 0001897612-26-000344 <b>Size:</b> 9 KB
Read moreDambkowski Carl 🟡 adjusted position in 5.5K shares (1 derivative) of Apogee Therapeutics, Inc. (APGE) at $85.89 Transaction Date: Apr 01, 2026 | Filing ID: 039709
Read moreHenderson Jane 🔴 sold 2.0K shares of Apogee Therapeutics, Inc. (APGE) at $85.46 Transaction Date: Apr 01, 2026 | Filing ID: 039708
Read moreHenderson Jane 🔴 sold 2.0K shares of Apogee Therapeutics, Inc. (APGE) at $85.00 Transaction Date: Mar 25, 2026 | Filing ID: 036332
Read moreNew Form SCHEDULE 13D/A - Apogee Therapeutics, Inc. <b>Filed:</b> 2026-03-27 <b>AccNo:</b> 0001104659-26-036265 <b>Size:</b> 18 KB
Read moreNew Form SCHEDULE 13G/A - Apogee Therapeutics, Inc. <b>Filed:</b> 2026-03-26 <b>AccNo:</b> 0000102909-26-000604 <b>Size:</b> 7 KB
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07027527 | An Active Comparator Safety Study Evaluating the Combination of APG777 + APG990… | Phase1 | Atopic Dermatitis | Active_Not_Recruiting | 2025-06-04 | 2027-12-01 | ClinicalTrials.gov |
| NCT06920901 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Immuno… | Phase1 | Asthma | Active_Not_Recruiting | 2025-03-27 | 2027-03-01 | ClinicalTrials.gov |
| NCT06395948 | A Study Evaluating APG777 in Atopic Dermatitis | Phase2 | Atopic Dermatitis | Active_Not_Recruiting | 2024-04-29 | 2028-06-01 | ClinicalTrials.gov |
| NCT02939807 | A Phase II Study of ABC294640 as Monotherapy in Patients With Advanced Hepatoce… | Phase2 | Carcinoma, Hepatocellular | Withdrawn | 2019-09-30 | 2024-01-30 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| ABC294640 | DRUG | Phase PHASE2 | Carcinoma, Hepatocellular | WITHDRAWN | NCT02939807 |
| Dupilumab | DRUG | Phase PHASE1 | Atopic Dermatitis | ACTIVE_NOT_RECRUITING | NCT07027527 |
| APG990 | DRUG | Phase PHASE1 | Atopic Dermatitis | ACTIVE_NOT_RECRUITING | NCT07027527 |
| Placebo | DRUG | Phase PHASE1 | Asthma | ACTIVE_NOT_RECRUITING | NCT06920901 |
| APG777 | DRUG | Phase PHASE1 | Atopic Dermatitis | ACTIVE_NOT_RECRUITING | NCT07027527 |